SCHEMBL6038758

SCHEMBL6038758

O=S(=O)(Nc1ncc(Br)nc1OCc1ccccc1)c1cccc(Br)c1

nearest known ligand 0.60

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 14/20 0.60
EDNRA P25101 3/20 0.47
PGR P06401 2/20 0.45
AR P10275 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038742 0.91 CCR4 (0.71) CCR4EDNRAAR
SCHEMBL6039082 0.90 CCR4 (0.58) CCR4EDNRA
SCHEMBL6039168 0.89 CCR4 (0.60) CCR4EDNRA
SCHEMBL6039070 0.89 CCR4 (0.72) CCR4EDNRAPGR
SCHEMBL6038799 0.89 CCR4 (0.57) CCR4EDNRAPGR
SCHEMBL6039161 0.88 CCR4 (0.63) CCR4EDNRAAR
SCHEMBL6039125 0.88 CCR4 (0.64) CCR4EDNRAPGR
SCHEMBL6038865 0.87 CCR4 (0.57) CCR4EDNRAPGRAR
SCHEMBL6038668 0.87 CCR4 (0.54) CCR4EDNRAPGRAR
SCHEMBL6038341 0.87 CCR4 (0.54) CCR4EDNRAPGRAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 CCR4 1/4885EDNRA 512/4885PGR 1603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.